



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Equivalent of Form PTO/SB/08A (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/580,263
\$ 371 Date	May 25, 2006
First Named Inventor	Sui Xiong CAI
Art Unit	1626
Examiner Name	(to be assigned)
Attorney Docket Number	1735.0940001/RWE/BAH

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JC/	US1	3,989,816	11-02-1976	Rajadhyaksha, V.J.	
JC/	US2	4,444,762	04-24-1984	Rajadhyaksha, V.J.	
JC/	US3	6,462,041 B1	10-08-2002	Cai et al.	
JC/	US4	6,335,429 B1	01-01-2002	Cai et al.	
JC/	US5	6,613,762 B2	09-02-2003	Cai et al.	
JC/	US6	7,176,234 B2	02-13-2007	Cai et al.	
	US7				
	US8				
	US9				
	US10				
	US11				
	US12				
	US13				
	US14				
	US15				
	US16				
	US17				
	US18				
	US19				
	US20				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
JC/	FP1	WO 2000/044216 A2	08-03-2000	Cytovia, Inc.		
JC/	FP2	WO 2004/002428 A2	01-08-2004	Cytovia, Inc.		
	FP3					
	FP4					
	FP5					
	FP6					
	FP7					
	FP8					
	FP9					

694099_1.DOC

Examiner Signature	/Janet Coppins/	Date Considered	03/26/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Application Number	10/580,263
\$ 371 Date	May 25, 2006
First Named Inventor	Sui Xiong CAI
Art Unit	1626
Examiner Name	(to be assigned)
Attorney Docket Number	1735.0940001/RWE/BAH

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/JC/	NPL1	Adawadkar, P.D. <i>et al.</i> , "Colouring Matters of <i>Garcinia morella</i> : Part VIII – Morellinol, Dihydromorelliflavone and Morelliflavone-7"-β-glucoside," <i>Indian J. Chem. 14B</i> :19-21, Council of Scientific & Industrial Research (1976)	
/JC/	NPL2	Adjei, A.A. <i>et al.</i> , "Synergy of the Protein Farnesyltransferase Inhibitor SCH66336 and Cisplatin in Human Cancer Cell Lines," <i>Clin. Cancer Res. 7</i> :1438-1445, American Association for Cancer Research, Inc. (2001)	
/JC/	NPL3	Ahmad, S.A. <i>et al.</i> , "Gamboge. Part II," <i>J. Chem. Soc. (C)</i> :772-779, The Chemical Society (1966)	
/JC/	NPL4	Almond, J.B. and Cohen, G.M., "The proteasome: a novel target for cancer chemotherapy," <i>Leukemia 16</i> :433-443, Nature Publishing Group (April 2002)	
/JC/	NPL5	Asano, J. <i>et al.</i> , "Cytotoxic Xanthones from <i>Garcinia hanburyi</i> ," <i>Phytochem. 41</i> :815-820, Elsevier Science Ltd. (1996)	
/JC/	NPL6	Batteux, F. <i>et al.</i> , "Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand," <i>J. Immunol. 162</i> :603-608, The American Association of Immunologists (1999)	
/JC/	NPL7	Bhat, H.B. <i>et al.</i> , "The Colouring Matters of <i>Garcinia morella</i> : Part V– Isolation of Desoxymorellin & Dihydroisomorellin," <i>Indian J. Chem. 2</i> :405-410, The Council of Scientific & Industrial Research (1964)	
/JC/	NPL8	Blanke, C.D., "Celecoxib With Chemotherapy in Colorectal Cancer," <i>Oncology (Huntingt) 16</i> (No. 4 Suppl. 3):17-21 (April 2002)	
/JC/	NPL9	Bairivant, M. <i>et al.</i> , "Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis," <i>Gastroenterology 116</i> :557-565, American Gastroenterological Association (1999)	
/JC/	NPL10	Cao, S.-G. <i>et al.</i> , "Novel Cytotoxic Polyphenylated Xanthonoids from <i>Garcinia gaudichaudii</i> (Guttiferae)," <i>Tetrahedron 54</i> :10915-10924, Elsevier Science Ltd. (1998)	

694529, I.DOC

Examiner Signature	/Janet Coppins/	Date Considered	03/26/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/068 (04-07)

Approved for use through 06/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number		
				10/580,263		
				\$ 371 Date		
				May 25, 2006		
				First Named Inventor		
				Sui Xiong CAI		
				Art Unit		
				1626		
				Examiner Name		
				(to be assigned)		
Sheet				2	of	5
				Attorney Docket Number		
				1735.0940001/RWE/BAH		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
/JC/	NPL11	Cao, S.-G. <i>et al.</i> , "Cytotoxic Caged Tetraprenylated Xanthonoids from <i>Garcinia gaudichaudii</i> (Guttiferae)," <i>Tetrahedron Lett.</i> 39:3353-3356, Elsevier Science Ltd. (1998)	
/JC/	NPL12	Chinnaiyan, A.M. <i>et al.</i> , "The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication," <i>Nat. Med.</i> 3:333-337, Nature Publishing Company (1997)	
/JC/	NPL13	Coven, T.R. <i>et al.</i> , "PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis," <i>Photodermatol. Photoimmunol. Photomed.</i> 15:22-27, Blackwell Munksgaard (1999)	
/JC/	NPL14	Crawford, K.W. and Bowen, W.D., "Sigma-2 Receptor Agonists Activate a Novel Apoptotic Pathway and Potentiate Antineoplastic Drugs in Breast Tumor Cell Lines," <i>Can. Res.</i> 62:313-322, American Association for Cancer Research, Inc. (January 2002)	
/JC/	NPL15	Database Biosis, Accession No. PREV199191109495, Qu, B.-X. <i>et al.</i> , "The Experimental Studies on Antineoplastic Action of Gambogic II," one page (1991)	
/JC/	NPL16	Giermasz, A. <i>et al.</i> , "Potentiating Antitumor Effects of a Combination Therapy with Lovastatin and Butyrate in the Lewis Lung Carcinoma Model in Mice," <i>Int. J. Cancer</i> 97:746-750, Wiley-Liss, Inc. (February 2002)	
/JC/	NPL17	Heenen, M. <i>et al.</i> , "Methotrexate induces apoptotic cell death in human keratinocytes," <i>Arch. Dermatol. Res.</i> 290:240-245, Springer-Verlag (1998)	
/JC/	NPL18	Infante, A.J. <i>et al.</i> , "The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis," <i>J. Pediatr.</i> 133:629-633, Mosby, Inc. (1998)	
/JC/	NPL19	Kalemkerian, G.P. and Ou, X., "Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines," <i>Cancer Chemother. Pharmacol.</i> 43:145-150, Springer-Verlag (1999)	
/JC/	NPL20	Karanjgaonkar, C.G. <i>et al.</i> , "Morellic, Isomorellic and Gambogic Acids," <i>Tetrahedron Letts.</i> 7:687-691, Pergamon Press Ltd. (1966)	

Examiner Signature	/Janet Coppins/	Date Considered	03/26/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/055 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/580,263
				\$ 371 Date	May 25, 2006
				First Named Inventor	Sui Xiong CAI
				Art Unit	1626
				Examiner Name	(to be assigned)
Sheet	3	of	5	Attorney Docket Number	1735.0940001/RWE/BAH

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
/JCI/	NPL21	Kelland, L.R. <i>et al.</i> , "Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer," <i>Clin. Cancer Res.</i> 7:3544-3550, American Association for Cancer Research, Inc. (2001)	
/JCI/	NPL22	Kyprianou, N. and Benning, C.M., "Suppression of Human Prostate Cancer Cell Growth By α 1-Adrenoceptor Antagonists Doxazosin and Terazosin via Induction of Apoptosis," <i>Cancer Res.</i> 60:4550-4555, American Association for Cancer Research, Inc. (2000)	
/JCI/	NPL23	Leong, Y.-W. <i>et al.</i> , "Forbesione, a Modified Xanthone from <i>Garcinia forbesii</i> ," <i>J. Chem. Res. (S)</i> :392-393, The Royal Society of Chemistry (1996)	
/JCI/	NPL24	Lin, L.-J. <i>et al.</i> , "Isogambogic Acid and Isomorellinol from <i>Garcinia Hanburyi</i> ," <i>Magn. Reson. Chem.</i> 31:340-347, John Wiley & Sons, Ltd. (1993)	
/JCI/	NPL25	Liu, W.M. <i>et al.</i> , "The <i>in vitro</i> activity of the tyrosine kinase inhibitor ST1571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents," <i>Br. J. Cancer</i> 86:1472-1478, Nature Publishing Group (May 2002)	
/JCI/	NPL26	López-Hoyos, M. <i>et al.</i> , "Regulation of B cell apoptosis by Bcl-2 and Bcl-X _L and its role in the development of autoimmune diseases (Review)," <i>Int. J. Mol. Med.</i> 1:475-483, D. A. Spandidos (1998)	
/JCI/	NPL27	Lu, G.B. <i>et al.</i> , "Isolation and Structure of Neo-gambogic Acid from Gamboge (<i>Garcinia hanburyi</i>)," <i>Yao Hsueh Hsueh Pao</i> 19:636-639, The Chinese Pharmaceutical Association and The Institute of Materia Medica (1984)	
/JCI/	NPL28	Motwani, M. <i>et al.</i> , "Augmentation of Apoptosis and Tumor Regression by Flavopiridol in the Presence of CPT-11 in Hct116 Colon Cancer Monolayers and Xenografts," <i>Clin. Cancer Res.</i> 7:4209-4219, American Association for Cancer Research, Inc. (2001)	
/JCI/	NPL29	Ohsako, S. and Elkon, K.B., "Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis," <i>Cell Death Differ.</i> 6:13-21, Nature Publishing Group (1999)	
/JCI/	NPL30	Ollis, W.D. <i>et al.</i> , "The Constitution of Gambogic Acid," <i>Tetrahedron</i> 21:1453-1470, Pergamon Press Ltd. (1965)	

Examiner Signature	/Janet Coppins/	Date Considered	03/26/2009
---------------------------	-----------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no responses are required to respond to a collection of information unless it contains a valid OMB control number.

Equivalent of Form PTO/SB/068 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/580,263
				\$ 371 Date	May 25, 2006
				First Named Inventor	Sui Xiong CAI
				Art Unit	1626
				Examiner Name	(to be assigned)
Sheet	4	of	5	Attorney Docket Number	1735.0940001/RWE/BAH

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
/JC/	NPL31	O'Reilly, L.A. & Strasser, A., "Review: Apoptosis and autoimmune disease," <i>Inflamm. Res.</i> 48:5-21, Birkhäuser Verlag, Basel (1999)	
/JC/	NPL32	Ozawa, M. <i>et al.</i> , "312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions," <i>J. Exp. Med.</i> 189:711-718, The Rockefeller University Press (1999)	
/JC/	NPL33	Qu, B.-X. <i>et al.</i> , "The Experimental Studies on Antineoplastic Action of Gambogic II," <i>Zhongguo Zhongliu Linchuang</i> 18:50-52, Tianjin: Tianjin-shi Yixue Zazhi She (1991)	
/JC/	NPL34	Rao, G.S.R. <i>et al.</i> , "Structure of moreollin, a pigment isolated from <i>Garcinia morella</i> Dessier," <i>Proc. Indian Acad. Sci.</i> 87A:75-86, The Indian Academy of Sciences (1978)	
/JC/	NPL35	Regar, E. <i>et al.</i> , "Stent development and local drug delivery," <i>Br. Med. Bull.</i> 59:227-248, Oxford University Press (2001)	
/JC/	NPL36	Rukachaisirikul, V. <i>et al.</i> , "Caged-Tetraprenylated Xanthenes from <i>Garcinia scortechinii</i> ," <i>Tetrahedron</i> 56:8539-8543, Elsevier Science Ltd. (2000)	
/JC/	NPL37	Savill, J., "Apoptosis in resolution of inflammation," <i>J. Leukoc. Biol.</i> 61:375-380, Society for Leukocyte Biology (1997)	
/JC/	NPL38	Sgadari, C. <i>et al.</i> , "HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma," <i>Nat. Med.</i> 8:225-232, Nature America Inc. (March 2002)	
/JC/	NPL39	Tai, D.-I. <i>et al.</i> , "Activation of Nuclear Factor KB in Hepatitis C Virus Infection: Implications for Pathogenesis and Hepatocarcinogenesis," <i>Hepatology</i> 31:656-664, W.B. Saunders Company (2000)	
/JC/	NPL40	Thoisson, O. <i>et al.</i> , "Cytotoxic Prenylxanthenes from <i>Garcinia bracteata</i> ," <i>J. Nat. Prod.</i> 63:441-446, American Chemical Society (2000)	

Examiner Signature	/Janet Coppins/	Date Considered	03/26/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/580,263
				\$ 371 Date	May 25, 2006
				First Named Inventor	Sui Xiong CAI
				Art Unit	1626
				Examiner Name	(to be assigned)
Sheet	5	of	5	Attorney Docket Number	1735.0940001/RWE/BAH

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
/JC/	NPL41	Vaishnaw, A.K. <i>et al.</i> , "The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations," <i>J. Clin. Invest.</i> 103:355-363, The American Society for Clinical Investigation Inc. (1999)	
/JC/	NPL42	Vilner, B.J. <i>et al.</i> , "Sigma-1 and Sigma-2 Receptors Are Expressed in a Wide Variety of Human and Rodent Tumor Cell Lines," <i>Cancer Res.</i> 55:408-413, American Association for Cancer Research, Inc. (1995)	
/JC/	NPL43	Wakisaka, S. <i>et al.</i> , "Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA)," <i>Clin. Exp. Immunol.</i> 114:119-128, Blackwell Science Ltd. (1998)	
/JC/	NPL44	Wu, J. <i>et al.</i> , "A highly rearranged tetraprenylxanthonoid from <i>Garcinia gaudichaudii</i> (Guttiferae)," <i>Tetrahedron Lett.</i> 42:727-729, Elsevier Science Ltd. (2001)	
/JC/	NPL45	Wu, X. <i>et al.</i> , "Mitochondrial Destabilisation and Caspase-3 Activation are Involved in the Apoptosis of Jurkat Cells Induced by Gaudichaudione A, a Cytotoxic Xanthone," <i>Planta Med.</i> 68:198-203, Georg Thieme Verlag Stuttgart (March 2002)	
/JC/	NPL46	Xu, Y.J. <i>et al.</i> , "Novel Cytotoxic, Polyprenylated Heptacyclic Xanthonoids from Indonesian <i>Garcinia gaudichaudii</i> (Guttiferae)," <i>Organic Lett.</i> 2:3945-3948, American Chemical Society (2000)	
/JC/	NPL47	Zhou, T. <i>et al.</i> , "Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits cell-mediated autoimmune diseases," <i>Nat. Med.</i> 5:42-48, Nature America Inc. (1999)	
/JC/	NPL48	Zou, C. <i>et al.</i> , "Combined effect of chemopreventive agent N-(4-hydroxyphenyl) retinamide (4-HPR) and γ -radiation on bladder cancer cell lines," <i>Int. J. Oncol.</i> 13:1037-1041, D. A. Spandidos (1998)	
	NPL49		
	NPL50		

Examiner Signature	/Janet Coppins/	Date Considered	03/26/2009
---------------------------	-----------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.